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Abstract
The phosphoinositide 3-kinase (PI3-kinase) and the mammalian target of rapamycin (mTOR) are two major signaling
molecules involved in growth and activation of mast cells (MC) and basophils (BA). We examined the effects of the dual
PI3-kinase/mTOR blocker NVP-BEZ235 on growth of normal and neoplastic BA and MC as well as immunoglobulin E
(IgE)-dependent cell activation. Growth of MC and BA were determined by measuring
3H-thymidine uptake and
apoptosis. Cell activation was determined in histamine release experiments and by measuring upregulation of CD63
and CD203c after challenging with IgE plus anti-IgE or allergen. We found that NVP-BEZ235 exerts profound inhibitory
e f f e c t so ng r o w t ho fp r i m a r ya n dc l o n e dn e o p l a s t i cM C .I nt h e MC leukemia cell line HMC-1, NVP-BEZ235 showed similar
IC50 values in the HMC-1.1 subclone lacking KIT D816V (0.025 mM) and the HMC-1.2 subclone expressing KIT D816V
(0.005 mM). Moreover, NVP-BEZ235 was found to exert strong growth-inhibitory effec t so nn e o p l a s t i cM Ci na
xenotransplant-mouse model employing NMR1-Foxn1
nu mice. NVP-BEZ235 also exerted inhibitory effects on cytokine-
dependent differentiation of normal BA and MC, but did not induce growth inhibition or apoptosis in mature MC or
normal bone marrow cells. Finally, NVP-BEZ235 was found to inhibit IgE-dependent histamine release in BA and MC
(IC50 0.5–1 mM) as well as anti-IgE-induced upregulation of CD203c in BA and IgE-dependent upregulation of CD63 in
MC. In summary, NVP-BEZ235 produces growth-inhibitory effects in immature neoplastic MC and inhibits IgE-
dependent activation of mature BA and MC. Whether these potentially beneficial drug effects have clinical implications
is currently under investigation.
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Introduction
Basophils (BA) and mast cells (MC) are effector cells of allergic
and other inflammatory reactions [1–3]. These cells produce a
number of biologically active mediator substances and express
receptors for immunoglobulin E (IgE) [1–6]. In response to IgE-
receptor cross-linking or other stimuli, BA and MC release
proinflammatory mediators and thereby contribute to the clinical
symptoms in allergic patients [4–8]. The capacity of BA and MC
to respond to an IgE-dependent trigger (allergen), also termed
releasability, depends on genetic factors, signal transduction
molecules, the maturation stage of cells, and the presence of
triggering cytokines [7–9] The severity of an allergic reaction
depends on additional factors, including the type of allergen, local
organ-specific factors, and the numbers of BA and MC involved in
the reaction [10–13]. Increased numbers of BA and/or MC are
seen in chronic inflammatory disorders, chronic infections, and in
certain hematologic disorders [3,12–14]. In systemic mastocytosis
(SM), MC numbers are highly elevated in various organs [3,12–
14]. In these patients, anaphylactic reactions may be life-
threatening and may occur even in the absence of specific
(detectable) IgE [12–14].
Activation of BA and MC through the IgE receptor is associated
with an increase in (activation-linked) cell surface antigens such as
CD63, and with activation of downstream signaling pathways [4–
6,15–19]. Major IgE receptor downstream pathways include the
MEK/ERK pathway and the phosphoinositide 3-kinase (PI3-
kinase)/Akt pathway [4–6,18,19]. Especially the latter pathway
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secretion [4–6,18,19]. In addition, the PI3-kinase is a regulator of
growth and survival of MC [20–22]. More recently, the PI3-kinase
has also been identified as a major signaling molecule responsible
for KIT-dependent differentiation and growth of neoplastic MC
harboring oncogenic KIT mutants [23,24]. Therefore, PI3-kinase
as well as PI3-kinase-downstream signaling molecules such as the
mammalian target of rapamycin (mTOR) are considered to
represent potential targets of therapy in diseases associated with
BA/MC activation or abnormal MC growth [25–27]. However,
most inhibitory compounds that have been developed in the past
cannot be applied in patients because of their unfavorable
pharmacological properties and toxicity.
NVP-BEZ235 is a novel orally-bioavailable PI3-kinase inhibitor
that has been described to exert growth-inhibitory effects on breast
cancer, prostate cancer, and myeloma cell lines [28–30]. NVP-
BEZ235 inhibits the activtion of all isoforms of the PI3-kinase as
well as mTOR [28]. Currently, NVP-BEZ235 is undergoing
evaluation in preclinical studies and clinical trials in cancer
patients.
In the current study, we examined the effects of NVP-BEZ235
on the growth of normal and neoplastic BA and MC, and on IgE
receptor-dependent activation. The results of our studies show that
NVP-BEZ235 is a potent inhibitor of growth and activation of
human BA and MC. Growth inhibitory effects of the drug were
seen not only in normal cells, but also in oncogene-transformed
neoplastic BA and MC. These results suggest that NVP-BEZ235
may be an interesting targeted drug for disorders associated with
abnormal growth or activation of BA or MC.
Results
NVP-BEZ235 inhibits the proliferation of neoplastic BA
and MC
As determined by
3H-thymidine uptake, NVP-BEZ235 was
found to inhibit spontaneous proliferation of KU812 cells, HMC-
1.1 cells, and HMC-1.2 cells in a dose-dependent manner
(Figure 1A). Interestingly, IC50 values obtained in HMC-1.1 cells
(0.025 mM) were slightly higher when compared to IC50 values
obtained in HMC-1.2 cells (0.005 mM) (Figure 1A). An unexpect-
ed observation was that the mTOR inhibitor RAD001 (ever-
olimus) produced clear growth inhibition in HMC-1.2 cells at low
concentrations (IC50,0.001 mM), whereas no effects were seen in
HMC-1.1 cells or KU812 cells (Figure 1B), suggesting that mTOR
may play a particular role in KIT D816V-dependent proliferation.
This assumption was confirmed by the fact that wortmannin did
not inhibit the proliferation in HMC-1.2 cells over the dose-range
tested (0.001–1 mM), whereas LY294002 (known to block mTOR
activity at high concentrations) was found to counteract prolifer-
ation of HMC-1.2 cells between 5 and 20 mM (Figure S1). We
were also able to show that NVP-BEZ235 dose-dependently
induces growth arrest in primary neoplastic cells obtained from
patients with KIT D816V+ SM (Table 1, Figure 1C). In normal/
reactive bone marrow cells (n=2 donors), no substantial effects of
NVP-BEZ235 were seen (Table 1).
We next examined the effects of NVP-BEZ235 and RAD001 on
cell cycle distribution in HMC-1 cells and KU812 cells. As
expected, NVP-BEZ235 produced a G1 cell cycle arrest in all
three cell lines (Figure S2). RAD001 was also found to induce a G1
cell cycle arrest, but the effect was less pronounced compared to
the effect of NVP-BEZ235 (Figure S2). We also examined the
effects of LY294002 and wortmannin on cell cycle distribution in
HMC-1 cells and KU812 cells. In these experiments, we found
that only LY294002, but not wortmannin produces a clear G1 cell
cycle arrest in HMC-1 cells and KU812 cells at relatively high
concentrations (Figure S2).
NVP-BEZ235 induces apoptosis in neoplastic BA and MC
To investigate the mechanism of drug-induced growth inhibition,
we examined NVP-BEZ235-exposed cells for signs of apoptosis. In
these experiments, NVP-BEZ235 was found to induce a dose-
dependent increase in apoptotic cells in all three cell lines examined
(Figure2A).Anunexpectedobservationwasthatapoptosis-inducing
effects of NVP-BEZ235 were stronger in HMC-1.1 cells compared
to HMC-1.2 cells (Figure 2A). These data suggest that KIT D816V
may induce resistance against the apoptosis-inducing effects of
NVP-BEZ235, whereas proliferation-inhibitory effects of the drug
are not altered by the KIT mutant. We also examined the effects of
RAD001 on survival of HMC-1 cells and KU812 cells. However,
the drug concentrations required to produce apoptosis were
relatively high, and even at the highest concentrations applied (5
and 10 mM), only a small subset of cells were found to be apoptotic
(Figure 2B). As a next step, we examined apoptosis-inducing effects
of NVP-BEZ235 and RAD001 on KU812 and HMC-1 cells by
AnnexinV/propidium iodide (PI) staining (Figure 2C), caspase
staining (Figure 2D), and in a Tunel assay (Figure 2E). In all three
assays, NVP-BEZ235 was found to induce apoptosisinthethree cell
lines tested (Figure 2C–2E). As expected, the effects of NVP-
BEZ235 on apoptosis-induction were stronger in HMC-1.1 cells
comparedtoHMC-1.2 (Figure2C–2E).RAD001alsoshowedsome
effects in these experiments. However, the effects of RAD001 were
farless pronounced compared totheeffectsseen with NVP-BEZ235
(Figure 2C–2E). In control experiments, NVP-BEZ235 showed no
substantial effects on cell viability or the percentage of apoptotic
cells (,5% apoptotic cells) in cord blood-derived cultured human
MC (data not shown).
NVP-BEZ235 exerts inhibitory effects on in vivo growth of
HMC-1.2 cells in a xenotransplantation model
To confirm the inhibitory effects of NVP-BEZ235 on growth of
HMC-1 cells, we examined the drug in a xenotransplant model
using HMC-1.2 cells and NMR1-Foxn1
nu mice. In these mice,
HMC-1 cells formed tumor nodules after subcutaneous injection
within 1–2 weeks. Administration of NVP-BEZ235 (40 mg/kg, per
os daily from day 5) resulted in a profound inhibition of tumor
formation in all mice examined (Figure 3A). By contrast, no
inhibitory effects of RAD001 on in vivo growth of HMC-1 cells in
nude mice could be substantiated (Figure 3B). All in all, these data
suggest that NVP-BEZ235 exerts anti-neoplastic effects on growth
of malignant MC in vivo.
NVP-BEZ235 inhibits cytokine-dependent differentiation
of human BA and MC
A generally accepted hypothesis is, that cytokine-dependent
growth of normal myeloid cells is dependent on PI3-kinase activity
[20–23]. We therefore asked whether NVP-BEZ235 would also
inhibit cytokine-dependent differentiation of normal BA and MC
from their immature cord blood-derived progenitors. In these
experiments, NVP-BEZ235 was found to suppress IL-3-dependent
differentiation of BA as well as SCF-dependent differentiation of
MC in a dose-dependent manner (Figure 4). In particular,
whereas, NVP-BEZ235 exerted only mild effects on the total
number of cultured cells, a significant inhibitory effect on cytokine-
dependent development of BA and MC was seen. IC50 values
obtained for NVP-BEZ235 in these experiments were by far lower
(,0.1 mM) compared to IC50 values obtained in cell activation
experiments.
Effects of NVP-BEZ235 on Basophils and Mast Cells
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signaling molecules in neoplastic BA (KU812) and MC
(HMC-1)
To confirm that NVP-BEZ235 exerts effects on HMC-1 cells
and KU812 cells through specific signal transduction molecules,
we performed flow cytometry experiments using antibodies against
phosphorylated Akt (pAkt, S473), pS6, and pSTAT5. We found
that NVP-BEZ235 substantially downregulated activation of Akt
and S6 in HMC-1.1 cells, and less effectively in HMC-1.2 and
KU812 cells (Figure 5A). As expected, RAD001 was found to
counteract expression of pS6 in HMC-1 cells and KU812 cells, but
did not inhibit pAkt (S473) (Figure 5A). Interestingly, NVP-
BEZ235 and RAD001 slightly decreased the expression of
pSTAT5 in HMC-1.1 cells and HMC-1.2 cells (Figure 5A). By
contrast, no effect of NVP-BEZ235 on pSTAT5 expression in
KU812 cells was seen. Data obtained by flow cytometry were
confirmed by Western blot experiments (Figure 5B and 5C).
Again, NVP-BEZ235 was found to downregulate expression of
pAkt (S473), pSTAT5, and pS6 in HMC-1.1 cells and HMC-1.2
cells, and expression of pAkt and pS6 in KU812 cells (Figure 5B
and 5C). Similar to our flow cytometry data, NVP-BEZ235 did
not downregulate activation of pSTAT5 in KU812 cells. As
determined by densitometry, RAD001 was found to slightly
upregulate expression of pAkt (Figure 5C). NVP-BEZ235 and
RAD001 were found to downregulate expression of pp70S6K and
p4EBP-1 in HMC-1 cells and KU812 cells (Figure 6). However,
whereas NVP-BEZ235 was found to exert strong inhibitory effects
on pAkt, pp70S6K, and p4EBP-1, RAD001, which is a selective
mTORC1 blocker, was found to strongly inhibit expression of
pp70S6K and p4EBP-1 (Figure 6), but did not inhibit expression
of pAkt (Figure 5). Finally, we explored whether NVP-BEZ235 or
RAD001 would interfere with pERK expression in HMC-1 cells
or KU812 cells. However, under the experimental conditions
applied, neither NVP-BEZ235 nor RAD001 were found to
Figure 1. Effects of NVP-BEZ235 on proliferation in HMC-1 cells and KU812 cells. A,B: HMC-1.1 cells (left panels), HMC-1.2 cells (middle
panels), and KU812 cells (right panels) were cultured in control medium (Co), control medium with DMSO 1:1,000 (DMSO Co), or with increasing
concentrations (0.001 mM–1 mM) of NVP-BEZ235 (A) or RAD001 (B) at 37uC for 48 hours. Thereafter,
3H-thymidine uptake was measured. Results show
the percentage of
3H-thymidine uptake compared to control (Co) and represent the mean6S.D. of three independent experiments in each cell line.
Asterisk (*): p,0.05. C: Bone marrow MNC from six patients with SM were incubated in control medium (Co) or in various concentrations of NVP-
BEZ235 (as indicated) at 37uC for 48 hours. Then,
3H-thymidine uptake was measured. Results show the percentage of
3H-thymidine uptake
compared to Co and represent the mean6S.D. of six donors. Asterisk (*): p,0.05.
doi:10.1371/journal.pone.0029925.g001
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cells (Figure S3).
NVP-BEZ235 inhibits IgE-dependent mediator release in
human MC
NVP-BEZ235 was found to counteract IgE-dependent release
of histamine in cultured cord blood progenitor-derived MC as well
as in mature human lung MC (Figure 7A). The effects of NVP-
BEZ235 on histamine release were mild, but dose-dependent and
seen at all concentrations of anti-IgE applied (Figure 7B). In
addition, NVP-BEZ235 was also found to inhibit the IgE-
dependent release of b-hexosaminidase in MC (Figure 7C).
However, compared to BA, higher concentrations of NVP-
BEZ235 (1–10 mM) were required to block mediator secretion in
MC. RAD001 showed no effects on mediator release in MC (not
shown).
NVP-BEZ235 inhibits IgE-dependent histamine release in
human BA
At 1 mM and 10 mM, NVP-BEZ235 was found to inhibit anti-
IgE-induced release of histamine from normal BA in all donors
(n=5) examined (Figure 8A). The effects of NVP-BEZ235 were
dose-dependent with IC50 values ranging between 0.5 and 1 mM.
NVP-BEZ235 was also found to counteract allergen-induced
histamine secretion in BA obtained from allergic patients
(Figure 8B). Again the effects of NVP-BEZ235 on allergen-
induced histamine release in BA were dose-dependent. To define
whether the effects of NVP-BEZ235 on histamine release were
mediated through mTOR, we applied the mTOR-specific drug
RAD001. However, in contrast to NVP-BEZ235, RAD001
showed no significant effects on IgE-mediated histamine release
(not shown). NVP-BEZ235 failed to inhibit the A23187-induced or
C5a-induced release of histamine in human BA (Figure 8C). These
data suggest that NVP-BEZ235 blocks IgE-mediated histamine
release through inhibition of PI3-kinase activity in human BA, a
conclusion that was supported by the observation that wortmannin
and LY294002 also blocked IgE-dependent histamine release in
normal BA (Figure 8A and 8B). The effects of wortmannin and
LY294002 on histamine release in normal BA were dose-
dependent (Figure S4).
NVP-BEZ235 inhibits the IgE-dependent upregulation of
activation-linked cell surface antigens on BA and MC
IgE receptor-dependent activation of BA and MC is accompa-
nied by an increased expression of activation-linked cell surface
antigens [15–17,31]. In the present study, we found that NVP-
BEZ235 inhibits anti-IgE-induced upregulation of CD63 and
CD203c on BA in a dose-dependent manner (IC50: 5–10 mM)
(Figure 9A). Wortmannin and LY294002 were also found to
inhibit anti-IgE-induced upregulation of CD63 and CD203c
(Figure 9A; Figure S5A). In cultured human MC and primary lung
MC, NVP-BEZ235 was found to inhibit the IgE-dependent
upregulation of CD63, whereas no substantial effects on IgE-
dependent upregulation of CD203c were seen (Figure 9B). To
study the mechanism of anti-IgE-induced upregulation of CD63
and CD203c, we performed cell surface and cytoplasmic staining
experiments with IgE receptor cross-linked BA and MC. In these
experiments, we found that IgE receptor cross-linking is followed
by a rapid increase in surface expression of CD63 and CD203c on
BA, whereas the intracellular levels of CD63 and CD203c slightly
decreased (Figure 9C, left panel). In lung MC, the same
phenomenon was observed for CD63. Both the anti-IgE-induced
upregulation of CD63 on the surface, and the decrease in
cytoplasmic CD63 were reverted by NVP-BEZ235 (Figure 9C,
right panel). In a next step, we examined the effects of NVP-
BEZ235 on expression of CD63 and CD203c on KU812 and
HMC-1 cells. We found that NVP-BEZ235 downregulated the
expression of CD63 in KU812 cells in a dose-dependent manner
(Figure S5B). By contrast, no effects of NVP-BEZ235 on
expression of CD63 in HMC-1 cells were found, and we were
also unable to demonstrate substantial effects of NVP-BEZ235 on
expression of CD203c on KU812 or HMC-1 cells (not shown).
Similarly, the mTOR inhibitor RAD001 and the other PI3-kinase
blockers applied (LY294002, wortmannin) did not inhibit the
Table 1. Effects of NVP-BEZ235 on proliferation of normal and neoplastic cells.*
Age Serum Tryptase NVP-BEZ235
Cell Type Diagnosis** f/m years (ng/ml) KIT D816V IC50 (mM)
BM MNC ISM f 69 16.8 + 0.1
BM MNC ISM m 82 30.7 + 0.1
BM MNC ISM f 44 14.0 + 0.1–0.5
BM MNC ISM f 39 11.5 + 0.1
BM MNC SSM f 56 133.0 + 0.1
BM MNC ISM m 66 65.4 + 0.1
BM MNC*** NHL – – n.d. n.d. .1
BM MNC*** NHL – – n.d. n.d. .1
HMC-1.1 MCL n.a. n.a. n.a. 2 0.025
HMC-1.2 MCL n.a. n.a. n.a. + 0.005
KU812 CML n.a. n.a. n.a. 2 0.01
*Proliferation was determined by measurement of
3H-thymidine uptake as described in the text.
**Diagnoses were established according to published criteria (12,13).
***Normal/reactive BM cells were obtained from patients with NHL without BM involvement.
Abbreviations: f, female; m, male; yrs, years; BM, bone marrow; MNC, mononuclear cells; ISM, indolent systemic mastocytosis; SSM, smoldering systemic mastocytosis;
NHL, Non Hodgkin’s Lymphoma; MCL, mast cell leukemia; CML, chronic myeloid leukemia; n.d., not determined; n.a., not applicable.
doi:10.1371/journal.pone.0029925.t001
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These data suggest that expression of CD63 and CD203c on
neoplastic BA and MC is not dependent on PI3-kinase activation.
Discussion
Growth, survival, and IgE-dependent activation of BA and MC
are regulated by a complex network of signal transduction
cascades and molecules, including various protein kinases [3–
5,21–24]. These signaling molecules are considered to represent
potential therapeutic targets in allergic patients as well as in
patients with MC proliferative disorders where abnormal MC
growth and activation represent major clinical problems [24–
27,32]. Recent data suggest that the PI3-kinase is a key regulator
of growth and activation of human BA and MC [20–24]. We here
show that the PI3-kinase/mTOR-targeting drug NVP-BEZ235
exerts major growth-inhibitory effects on neoplastic BA and MC,
and inhibits IgE-dependent mediator secretion.
Initially, NVP-BEZ235 was developed as a dual inhibitor of
PI3-kinase and mTOR [28]. In the present study, we were able to
confirm the PI3-kinase-blocking and mTOR-targeting activity of
the drug. In particular, as assessed by Western blotting and flow
cytometry, NVP-BEZ235 was found to downregulate the
expression of pAkt (S473) and pS6 in HMC-1 cells, whereas the
mTOR-targeting drug RAD001 only blocked pS6 activity.
However, depending on the cell type and function analyzed
(growth or activation), PI3-kinase and mTOR may play a quite
different role. In fact, BA- and MC-activation could only be
downregulated by PI3-kinase inhibitors but not by the mTOR
blocker RAD001. On the other hand, mTOR seems to play a
particular role in neoplastic growth of MC carrying the KIT
mutant D816V.
Interestingly, RAD001 did not mimic most of the effects of
NVP-BEZ235 on mediator secretion in BA or MC, and where
effects of RAD001 were seen, they were less pronounced or
neglectible compared to effects seen with NVP-BEZ235. These
data suggest that the inhibitory effects of NVP-BEZ235 on BA and
MC are primarily mediated via PI3-kinase inhibition rather than
mTOR inhibition, and that other PI3-kinase-downstream signal-
ing molecules may be involved in the effects of NVP-BEZ235 on
activation of BA and MC. The identity of these downstream
molecules remains at present unknown. Another explanation
would be that RAD001 is a selective mTORC1 inhibitor that is
known to even activate Akt in a negative feed-back loop.
Accordingly, we found that RAD001 slightly upregulates pAkt
expression in HMC-1 cells. An alternative explanation for the
differential effects of RAD001 and NVP-BEZ235 would be that
NVP-BEZ235 acts on BA and MC via PI3-kinase/mTOR-
independent targets. Indeed, in KU812 cells, NVP-BEZ235
showed only slight effects on PI3-kinase phosphorylation, although
the drug exerted strong growth-inhibitory effects. On the other
hand, the target spectrum of NVP-BEZ235 has been well-defined
and no other major kinase targets have been identified so far [28].
Finally, most effects of NVP-BEZ235 on normal BA were copied
by the PI3-kinase inhibitors wortmannin and LY294002. An
interesting exception and observation was that LY294002 did not
Figure 2. Effects of NVP-BEZ235 on survival of HMC-1 cells and KU812 cells. A,B: HMC-1.1 cells (left panels), HMC-1.2 cells (middle panels),
and KU812 cells (right panels) were cultured in control medium (Co), LY294002 (20 mM), or increasing concentrations (0.001 mM–10 mM) of NVP-
BEZ235 (A) or RAD001 (B) at 37uC for 48 hours. Then, the numbers (percentage) of apoptotic cells was counted on Giemsa-stained cytospin slides.
Results represent the mean6S.D. of three independent experiments. Asterisk (*) indicates p,0.05. C: HMC-1.1 cells (upper panels), HMC-1.2 cells
(middle panels) and KU812 cells (lower panels) were incubated in control medium (Co) (left panels) or in medium containing NVP-BEZ235, 1 mM
(middle panels) or RAD001, 1 mM (right panel) for 48 hours. After incubation, cells were examined for combined AnnexinV/PI staining by flow
cytometry. D: HMC-1.1 (left panel), HMC-1.2 (middle panel), and KU812 cells (right panel) were incubated in control medium (Co) or in various
concentrations of NVP-BEZ235 or RAD001 as indicated (37uC, 48 hours). Then, the percentage of active caspase 3-positive cells was determined by
flow cytometry. Results represent the mean6S.D. of three independent experiments. Asterisk (*) indicates p,0.05. E: HMC-1.1 cells (upper panels),
HMC-1.2 cells (middle panels) and KU812 cells (lower panels) were incubated in control medium (Co) or in medium containing NVP-BEZ235 (1 or
10 mM) or RAD001 (1 or 10 mM) (as indicated) at 37uC for 48 hours. Thereafter, cells were harvested and subjected to Tunel assay and examined by
fluorescence microscopy.
doi:10.1371/journal.pone.0029925.g002
Figure 3. Effect of NVP-BEZ235 on in vivo growth of HMC-1.2 cells. Female NMRI-Foxn1
nu mice were inoculated with HMC-1.2 cells and were
randomized into a treatment group (drug gavaging) and a control group. A: The treatment group (7 mice) received 40 mg/kg NVP-BEZ235 dissolved
in NMP and PEG300 per os every day, and the control group (6 mice) received NMP and PEG300 alone for 22 days. B: The treatment group (5 mice)
received 5 mg/kg RAD001 dissolved in distilled water per os, and the control group (5 mice) received sodium chloride per os for 19 days. Tumor size is
shown in the vertical axis and is expressed in mm
3. Results represent the mean6S.D. in each group. Asterisk (*) indicates p,0.05 compared to the
control group.
doi:10.1371/journal.pone.0029925.g003
Effects of NVP-BEZ235 on Basophils and Mast Cells
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suggesting that BA in allergic patients may be resistant against
release-inhibitory effects of this agent.
An unexpected result was that NVP-BEZ235 not only
downregulates expression of pAkt (S473) and pS6 in HMC-1
cells, but also expression of pSTAT5. This is of particular interest
for several reasons. First, STAT5 has been implicated as a major
regulator of growth, survival, and activation of MC [24,33–35].
Second, it has been described that in neoplastic MC, STAT5
forms a signaling complex with PI3-kinase that can be triggered/
activated by oncogenic KIT mutants [24]. Based upon these
observations, it is tempting to speculate that NVP-BEZ235 acts
inhibitory on this PI3-kinase/STAT5 signaling complex in KIT
D816V+ neoplastic MC. The possibility that NVP-BEZ235
directly binds to STAT5 seems rather unlikely.
Although NVP-BEZ235 was found to inhibit both the
proliferation and activation of human BA and MC in this study,
some interesting differences concerning drug actions were
observed. The most apparent and probably relevant difference
was the higher IC50 values required to block cell activation and
mediator secretion compared to doses required for growth-
inhibition. The biochemical basis of this difference remains
unknown. Possible explanations would be different targets
involved in the reactions or the different time of incubation used
to treat cells. Clinically, the lower IC50 values would argue for the
use of NVP-BEZ235 to counteract growth of neoplastic BA or MC
rather than to block BA- or MC-activation in allergic disorders.
We were also able to confirm the major growth-inhibitory
effects of NVP-BEZ235 on neoplastic MC in a xenotransplant
mouse model using HMC-1.2 cells. Again NVP-BEZ235 was
found to block the growth of HMC-1.2 in this model, whereas
RAD001 showed no substantial effects. This discrepancy may be
due to the lower dose of RAD001 applied (5 mg/kg/day)
compared to the dose of NVP-BEZ235 (40 mg/kg/day). Howev-
er, we were unable to increase the dose of RAD001 because of its
known toxicity. The strong inhibitory effects of NVP-BEZ235 on
in vivo growth of HMC-1 cells may be of clinical significance.
An interesting observation was that NVP-BEZ235 produces
differential effects on survival in HMC-1.1 cells lacking KIT
D816V and HMC-1.2 cells expressing KIT D816V. In particular,
although at high concentrations, the drug produced massive
apoptosis in HMC-1.1 cells (.90% apoptotic cells), only a small
subset of HMC-1.2 cells underwent apoptosis regardless of the
drug concentrations applied. This was an unexpected outcome as
the effects of NVP-BEZ235 on proliferation of the two HMC-1
subclones were comparable. One possible explanation for these
results would be that the KIT mutation D816V confers specific
resistance against apoptosis-inducing effects of NVP-BEZ235. In
this regard it is noteworthy that this mutant also causes resistance
against established KIT kinase inhibitors including imatinib
[36,37]. An alternative explanation would be that the effects of
NVP-BEZ235 on growth of HMC-1.2 cells were primarily
mediated through inhibition of the cell cycle-regulator mTOR
rather than PI3-kinase inhibition. This assumption would be
supported by the observation that the mTOR blocker RAD001
produced marked growth inhibition in HMC-1.2 cells expressing
KIT D816V, but not in HMC-1.1 cells lacking KIT D816V,
which confirmed previous data obtained with the mTOR-blocker
rapamycin [38,39]. Moreover, the PI3-kinase blocker LY294002
only produced growth inhibitory effects in HMC-1.2 cells when
applied at high concentrations known to block mTOR activity,
whereas no effects were seen with wortmannin. All in all, these
Figure 4. Effects of NVP-BEZ235 on cytokine-dependent differentiation of human BA and MC. A: Isolated cord blood MNC (0.5610
6/ml)
were cultured in 6-well plates (Costar, Cambridge, MA) in RPMI medium containing 10% FCS and IL-3 (100 ng/ml) with or without NVP-BEZ235
(0.001–0.1 mM) at 37uC for two weeks. Thereafter, the total cell numbers per well (left panel), the total numbers of BA per well determined from total
cell counts and differential counts obtained in Giemsa-stained slides (middle panel), and the total cellular histamine levels per well assessed by
radioimmunoassay (right panel), were determined. B: Cord blood MNC were cultured in RPMI medium containing 10% FCS, SCF (100 ng/ml), and IL-6
(100 ng/ml), with or without NVP-BEZ235 (0.001–0.01 mM) at 37uC for four weeks. Thereafter, the total cell numbers per well (left panel), the total
numbers of MC per well determined from total cell counts and differential counts (middle panel), and the total cellular histamine levels per well (right
panel), were determined. Results represent the mean6S.D of three independent experiments. Asterix (*): p,0.05.
doi:10.1371/journal.pone.0029925.g004
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29925Figure 5. Effects of NVP-BEZ235 on expression of pAkt, pS6, and pSTAT5 in HMC-1 cells and KU812 cells. A: HMC-1.1 cells (upper
panel), HMC-1.2 cells (middle panel), and KU812 cells (lower panel) were incubated with control medium (Co) or medium containing NVP-BEZ235 (1
or 10 mM) or RAD001 (1 or 10 mM) at 37uC for 4 hours. Thereafter, cells were permeabilized and stained with antibodies against pAkt (S473), pS6, or
pSTAT5 as described in the text. Expression of phosphorylated (p) signaling molecules in HMC-1 cells and KU812 cells were determined by flow
cytometry. Results show the staining index (mean fluorescence intensity values corrected for the isotype) and represent the mean6S.D. from three
independent experiments. B: HMC-1.1 cells (upper panel), HMC-1.2 cells (middle panel), and KU812 cells (lower panel) were cultured in the absence or
presence of NVP-BEZ235 (1 mM) RAD001 (1 mM) at 37uC for 4 hours. Thereafter, cells were lysed and Western blotting was performed using antibodies
against pAkt (S473), Akt, pSTAT5, STAT5, pS6 and b-Actin. C: Western blot results were quantified by densitometry in HMC-1.1 cells (upper panel),
HMC-1.2 cells (middle panel), and KU812 cells (lower panel). Results represent the mean6S.D. from three independent experiments.
doi:10.1371/journal.pone.0029925.g005
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MC may be particularly sensitive against mTOR-targeting drugs.
Since mTOR is a major regulator of cell cycle progression we
were also interested to learn whether NVP-BEZ235 would
interfere with cell cycle progression in HMC-1 cells and KU812
cells. Indeed, NVP-BEZ235 was found to induce a G1 cell cycle
arrest in HMC-1.1, HMC-1.2, and KU812 cells. RAD001 also
induced a G1 cell cycle arrest although the effect of RAD001 was
less pronounced compared to NVP-BEZ235. Finally, LY294002
also produced a G1 cell cycle arrest in these cells at high
concentrations, whereas wortmannin showed no effects. These
results were somehow unexpected as RAD001 and LY294002 did
not produce growth inhibition in HMC-1.1 cells, and RAD001
also failed to inhibit the proliferation of KU812 cells, whereas
NVP-BEZ235 exerted effects on growth in all cell lines. This
discrepancy may be explained by the fact that not only mTOR but
also other (PI3-kinase-downstream) cell cycle regulators play a role
in the proliferation of these cells. Alternatively, HMC-1.1 cells are
resistant against RAD001, LY294002, and wortmannin indepen-
dent of mTOR and PI3-kinase-activity.
Several cell surface molecules are typically upregulated on BA
and MC after cross-linking of IgE receptors [15–17,40]. In
addition, these activation-linked surface antigens are often
overexpressed on neoplastic MC when compared to normal cells
[13,14,40]. We asked whether NVP-BEZ235 would interfere with
IgE-mediated expression of CD63 and CD203c on BA and MC.
In these experiments, we found that NVP-BEZ235 inhibits the
IgE-dependent upregulation of CD203c on BA and IgE-
dependent upregulation of CD63 on MC. By contrast, no drug
effect on IgE-dependent expression of CD63 on BA or IgE-
mediated expression of CD203c on MC was seen. These
observations suggest that NVP-BEZ235 may be insufficient to
block all relevant pathways in activated BA or MC. Alternatively,
expression of CD63 in BA and of CD203c on MC is regulated by
PI3-kinase-independent mechanisms. In this regard it is notewor-
thy, that NVP-BEZ235 did not counteract expression of CD63 or
CD203c on HMC-1 cells, and in KU812 cells only a slight effect
on CD63 expression was seen.
Based on the intriguing effects of NVP-BEZ235 on growth
(survival) and activation of BA and MC, one could speculate on
clinical applications and possible indications in future trials.
Likewise, in advanced SM, patients suffer not only from the
aggressive and sometimes devastating infiltration of MC, but also
from mediator-related symptoms [11–13]. For these patients, a
drug that would block both MC growth and MC activation would
be of interest. Our in vitro data and data obtained in a mouse
xenotransplant model would be in favor of such a new treatment
concept. However, so far no clinical studies using NVP-BEZ235 in
allergic patients or patients with mastocytosis have been
conducted. In summary, our data show that NVP-BEZ235
inhibits growth and activation of human BA and MC. Further
preclinical studies are required to confirm this drug effect and to
explore whether the drug is a candidate to be tested in patients
with MC disorders or MC/BA activation.
Materials and Methods
Ethics Statement
All studies were approved by the institutional review board of
the Medical University of Vienna and conducted in accordance
with the declaration of Helsinki. Written informed consent was
obtained from patients or mothers (cord blood) in each case.
Animal studies were approved by the ethics committee of the
Medical University of Vienna (3544/115-10/08), and carried out
in accordance with guidelines for animal care and protection and
protocols approved by the Austrian law and the ethics committee
of the Medical University of Vienna (GZ 66.009/0322-II/10b/
2008).
Reagents
NVP-BEZ235 [28] and RAD001 (everolimus) were kindly
provided by Novartis Pharma AG, Basel, Switzerland. Stock
solutions of drugs were prepared by dissolving in dimethylsulfoxide
(DMSO) (Merck, Darmstadt, Germany). Histamine release buffer
(HRB), anti-IgE antibody E-124.2.8, and a histamine radioimmu-
noassay (RIA) were purchased from Immunotech (Marseille,
France). RPMI 1640 medium, Iscove’s modified Dulbecco’s
medium (IMDM), and fetal calf serum (FCS) were from PAA
laboratories (Pasching, Austria), Ca-ionophore A23187 and
recombinant C5a from Sigma Aldrich (St. Louis, MO),
LY294002 and wortmannin from Calbiochem (San Diego, CA),
and L-glutamine from Gibco Life Technologies (Gaithersburg,
MD). Recombinant human (rh) interleukin (IL)-3, IL-4, IL-6, and
stem cell factor (SCF) were from Novartis Pharma AG. NIP(5)-
BSA was purchased from Biosearch Technologies (Novato, CA), a
human NIP-specific IgE (clone Jw8.1) from AbD Serotec
(Du ¨sseldorf, Germany), collagenase type II from Worthington
(Lakewood, NJ), Stem Span serum-free medium (SFM) from Stem
Cell Technologies (CellSystems, St Katharinen, Germany), and
the CD133 Microbead Kit from Miltenyi Biotec (Bergisch
Gladbach, Germany). The FITC-labeled CD63 antibody CLB-
gran12 and PE-labeled CD203c antibody 97A6 were purchased
from Beckman Coulter (Fullerton, CA), the unlabeled monoclonal
antibody (mAb) CLB-gran12 from Sanquin Reagents (Amster-
dam, Netherlands), and a PE-labeled and unlabeled CD203c mAb
(NP4D6) from Biolegend (San Diego, CA).
Isolation and culture of blood BA and MC
Primary BA were obtained from the peripheral blood of 5
healthy donors and 5 patients allergic to the birch pollen allergen
Bet v 1. For surface staining experiments, BA were examined in
heparinized whole blood samples. For histamine release experi-
ments, BA were enriched by dextran sedimentation [41]. MC-
cultures were generated using CD133+ cord blood progenitors as
Figure 6. Effects of NVP-BEZ235 on expression of p4EBP-1 and
pp70S6K in HMC-1 cells and KU812 cells. HMC-1.1 cells (left
panel), HMC-1.2 cells (middle panel), and KU812 cells (right panel) were
cultured in the absence or presence of NVP-BEZ235 (1 mM) or RAD001
(1 mM) at 37uC for 4 hours. Thereafter, cells were lysed, and Western
blotting was performed using antibodies against p4EBP-1, pp70S6K,
and b-Actin.
doi:10.1371/journal.pone.0029925.g006
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cord blood mononuclear cells (MNC) using magnetic microbeads
and the QuadroMACS magnetic separator (Miltenyi Biotec). The
purity of isolated CD133+ cells was .97%. Isolated cells
(0.5610
6/ml) were cultured in 6-well plates (Costar, Cambridge,
MA) in SFM with SCF (100 ng/ml), IL-6 (100 ng/ml), and IL-3
(30 ng/ml) for 2 weeks, and thereafter in SCF and IL-6 without
IL-3. After 4 weeks, RPMI 1640 medium containing 10% FCS
was used instead of SFM. Cytokines were replaced weekly. After 7
weeks, 70–80% of cells were MC as evidenced by Wright-Giemsa
staining. Human lung MC were enriched from surgical specimens
of 5 patients with bronchiogenic carcinoma as described [43]. In
brief, tissue was placed in Tyrode’s buffer, cut into small pieces,
and washed extensively in Tyrode’s buffer. Then, tissue fragments
were incubated in collagenase type II at 37uC for 60 minutes.
Isolated cells were examined for viability and percentage of MC by
Giemsa staining. Lung MC were kept in culture in RPMI 1640
medium and 10% FCS at 37uC for 2–5 days before used. In 5
patients with SM, bone marrow MNC were isolated using Ficoll.
Culture of KU812 cells and HMC-1 cells
The human BA cell line KU812 was kindly provided by Dr. K.
Kishi (Kumamoto University, Kumamoto, Japan). KU812 cells
were cultured in RPMI1640 medium with 10% FCS (37uC, 5%
CO2). The human MC leukemia cell line HMC-1 [44] was kindly
provided by Dr. J. H. Butterfield (Mayo Clinic, Rochester, MN).
Figure 7. Effects of NVP-BEZ235 on mediator secretion in human MC. A: IgE-preloaded cultured cord blood-derived MC (left panel) and IgE-
preloaded lung MC (right panel) were incubated in control medium, various concentrations of NVP-BEZ235 (as indicated), LY294002 (20 mM), or
wortmannin (1 mM) (30 minutes, 37uC). Then, cells were challenged with anti-IgE (10 mg/ml) at 37uC for 30 minutes. After incubation, histamine
release was determined. Results show the percentage of released histamine and represent the mean6S.D. of four (cultured MC, left panel) or five
independent experiments (5 lung MC samples, right panel). Asterisk (*): p,0.05. B: Cultured MC were incubated in the presence of control medium
(indicated by black bars) or medium containing NVP-BEZ235, 10 mM (open bars) for 30 minutes at 37uC. Then, cells were incubated with various
concentrations of anti-IgE as indicated. After incubation, supernatants and lysates were harvested and examined for histamine content. Histamine
release was calculated as percent of total histamine. Results show the percent of released histamine and are expressed as mean6S.D. of three
independent experiments. Asterisk (*): p,0.05. C: MC preloaded with NIP(5)-BSA-specific IgE were cultured in control medium (Co) or in various
concentrations of NVP-BEZ235 (0.001–10 mM) for 30 minutes at 37uC. Thereafter, cells were washed and incubated with NIP(5)-BSA (100 ng/ml) for
90 minutes (37uC). Then, cell-free supernatants were collected and b-hexosaminidase release was measured. Results are expressed in percent of
response induced by anti-IgE without NVP-BEZ235 and represent the mean6S.D of three independent experiments. Asterisk (*) indicates p,0.05.
doi:10.1371/journal.pone.0029925.g007
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KIT mutation V560G, and HMC-1.2 harboring KIT V560G and
KIT D816V [36]. HMC-1 cells were grown in IMDM plus 10%
FCS (37uC, 5% CO2).
Measurement of
3H-thymidine uptake
HMC-1 cells, KU812 cells, and primary bone marrow derived
cells obtained from 6 patients with SM (indolent SM, n=5,
smolderingSM,n=1)wereincubated incontrolmedium or various
concentrations of NVP-BEZ235 (0.001–5 mM) at 37uC for
48 hours. Cell lines were also incubated with RAD001 (0.001–
1 mM) for 48 hours. Thereafter, 0.5 mCi
3H-thymidine was added
(37uC, 16 hours). Cells were harvested on filter membranes
(Packard Bioscience, Meriden, CT) in a Filtermate 196 harvester
(Packard Bioscience). Filters were air-dried, and the bound
radioactivity was counted in a b-counter (Top-Count NXT,
Packard Bioscience). All experiments were performed in triplicates.
Evaluation of apoptosis by morphology and Tunel assay
The effects of NVP-BEZ235 and RAD001 on apoptosis in
KU812 cells and HMC-1 cells were analyzed by morphologic
examination (light microscopy) and a Tunel (in situ Terminal
transferase-mediated dUTP-fluorescence Nick End-Labeling) as-
say using the ‘In situ cell death detection kit-fluorescein’ (Roche
Diagnostics, Mannheim, Germany) [45]. For morphologic exam-
ination, cells were incubated with NVP-BEZ235 (0.001–10 mM)
and RAD001 (0.001–10 mM), LY294002 (20 mM), or control
medium at 37uC for 48 hours. The percentage of apoptotic cells
was quantified on Wright-Giemsa-stained cytospin slides. In Tunel
assay experiments, cells were incubated with NVP-BEZ235 (1 or
10 mM), RAD001 (1 or 10 mM), or control medium at 37uC for
24 hours. The Tunel assay was performed as reported [45]. Cells
were analyzed on an Olympus AX-1 fluorescence microscope
equipped with 1006/1.35 UPlan-Apo objective lense (Olympus).
Figure acquisition was performed using Olympus DP11 camera
Figure 8. Effects of NVP-BEZ235 on IgE-mediated histamine release in human BA. BA obtained from healthy donors (A) or patients allergic
to Bet v 1 (B) were preincubated with control medium (Medium Co), various concentrations of NVP-BEZ235 (as indicated), LY294002 (20 mM), or
wortmannin (1 mM) at 37uC for 30 minutes. Then, cells were exposed to anti-IgE (1 mg/ml; healthy controls) or recombinant allergen (0.1 mg/ml of Bet
v 1; allergic patients) at 37uC for 30 minutes. After centrifugation, histamine concentrations were determined in supernatants and cell-lysates by RIA.
Histamine release is expressed as percentage of total histamine. Results represent the mean6S.D. from five donors. Asterisk (*) indicates p,0.05. C:
BA obtained from one healthy donor were incubated in control medium (¤-¤) or medium containing NVP-BEZ235, 10 mM( &-&) for 30 minutes at
37uC. Then, cells were incubated with various concentrations (as indicated) of anti-IgE (left panel), Ca-ionophore A23187 (middle panel), or
recombinant C5a (right panel) for another 30 minutes (37uC). After incubation, supernatants and lysates were harvested and examined for their
histamine content. Histamine release was calculated as percent of total histamine. Data are expressed as mean6S.D. of triplicates.
doi:10.1371/journal.pone.0029925.g008
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PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e29925Figure 9. Effects of NVP-BEZ235 on expression of activation-linked cell surface antigens on BA and MC. A: BA in whole blood samples
were preincubated in control medium (Medium Co) or in medium containing various concentrations of NVP-BEZ235 (0.001–10 mM), LY294002
(20 mM), or wortmannin (1 mM) at 37uC for 15 minutes. Then, cells were exposed to anti-IgE antibody E-124.2.8 (1 mg/ml) for another 15 minutes
(37uC). Thereafter, cells were stained with mAb directed against CD63 (left panel) or CD203c (right panel), and analyzed by multicolor flow cytometry
as described in the text. BA were defined as CD203c-positive cells in all samples. Anti-IgE-induced upregulation of CD antigens was calculated from
mean fluorescence intensities (MFIs) obtained with stimulated (MFIstim) and unstimulated (MFIcontrol) cells and was expressed as SI
(MFIstim:MFIcontrol). Results show SI values and represent the mean6S.D. from five normal donors (the same as shown in Figure 1A). Asterisk (*)
indicates p,0.05. B: IgE-preloaded cultured MC (left panel) or IgE-preloaded lung MC (right panel) were incubated in control medium (Co) or in
various concentrations of NVP-BEZ235 (as indicated) at 37uC for 40 minutes. Then, cells were incubated with anti-IgE antibody E-124.2.8 (10 mg/ml)
for 30 minutes (37uC). After incubation, expression of CD63 (¤-¤) and CD203c (%-%) on MC was analyzed by flow cytometry. Results show the
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San Jose, CA). Magnification, 6400.
Application of NVP-BEZ235 in a xenotransplantation
model
Female NMRI-Foxn1
nu mice (4–5 week old) were purchased
from Charles River Laboratories (Sulzfeld, Germany). Mice were
housed in barrier facilities with a 12 hour-light/dark cycles. In
each mouse, 3610
7 HMC-1.2 cells were inoculated subcutane-
ously in the right and left flank. Five days after inoculation, mice
were divided into two groups, a control group (n=6 or n=5) and
a treatment group (n=7 or n=5). In the treatment group, mice
received 40 mg/kg NVP-BEZ235 dissolved in 200 ml N-methyl-2-
pyrrolidone (NMP) and polyethylene glycol 300 (PEG300; Sigma-
Aldrich) or 5 mg/kg RAD001 dissolved in 200 ml distilled water
per os (gavaging) daily for up to 22 days. In the control group, mice
received NMP and PEG300 alone or sodium chloride (water
control). Tumor size was inspected daily and was measured (in
mm
3) by caliper using the formula: a
2 * b/2 (a: length of tumor; b:
tumor width). On day 22, mice were sacrificed by euthanization.
Tumors were collected and dispersed by collagenase digestion
[44,45]. In each case, xenotransplant tumor-derived cells were
found to exhibit morphologic and phenotypic properties of HMC-
1 cells (not shown).
BA differentiation assay and MC differentiation assay
CD133+ cord blood progenitor cells were isolated from MNC
using magnetic beads as reported [42]. Isolated progenitors were
cultured in control medium or in the presence of either IL-3
(100 ng/ml) (BA differentiation assay) or SCF (100 ng/ml) plus
IL-6 (100 ng/ml) (MC differentiation assay) at 37uC for 14 days
(BA) or 28 days (MC) as reported [46,47] Thereafter, cultures were
harvested and examined for total cell counts, percentage of BA or
MC by Giemsa-staining, and absolute numbers of BA and MC per
well. For further objective quantification of BA- and MC
differentiation, equal suspension volumes of day-14-samples (BA)
or day-28-samples (MC) were examined for total cellular
histamine-content by RIA as reported [46,47].
Staining with mAb and flow cytometry
To examine drug effects on expression of CD63 and CD203c,
flow cytometry was performed. BA were incubated with NVP-
BEZ235 (0.001–10 mM), RAD001 (0.001–10 mM), LY294002
(0.01–30 mM), wortmannin (0.0001–1 mM), or control medium
for 15 minutes (37uC). Then, BA were washed, incubated with
anti-IgE mAb E-124.2.8 (1 mg/ml) at 37uC for 15 minutes,
washed, then were subjected to erythrocyte lysis, and then
analyzed by multicolor flow cytometry using mAb against CD63
and CD203c as described [31,48,49]. Anti-IgE-induced upregula-
tion of CD63 and CD203c was calculated from mean fluorescence
intensities (MFI) obtained with stimulated (MFIstim) and un-
stimulated (MFIcontrol) cells, and expressed as stimulation index
(SI=MFIstim:MFIcontrol) [31,48,49]. Cultured IgE-loaded MC
were incubated with NVP-BEZ235 (0.001–10 mM), RAD001
(0.001–10 mM), or control medium for 40 minutes (37uC).
Thereafter, MC were challenged with NIP(5)-BSA (100 ng/ml)
in phenolred-free medium plus 0.1% BSA for 90 minutes (37uC).
Expression of CD63 and CD203c was analyzed as reported
[31,48,49]. KU812 and HMC-1 cells were incubated with NVP-
BEZ235 (0.001–10 mM), RAD001 (0.001–10 mM), LY294002
(20 mM), wortmannin (1 mM), or control medium for 24 or
48 hours, before being stained with mAb against CD63 or
CD203c. Expression of cell surface antigens was analyzed on a
FACSScan (Becton Dickinson Biosciences, San Jose, CA). All
staining reactions were controlled by isotype-matched antibodies.
For staining of cytoplasmic molecules, KU812 and HMC-1 cells
were permeabilized by methanol (220uC, 15 minutes) and then
incubated with mAb against phosphorylated Akt (pAkt, S473)
(M89-61), pS6 (N7-548), pSTAT5 (clone 47), or activated caspase
3 (C92-605) (all from Becton Dickinson Biosciences) for 30 min-
utes. Then, cells were washed and analyzed on a FACSCalibur
(Becton Dickinson Biosciences). In a separate set of experiments,
blood BA and lung MC were stained with mAb against CD63 and
CD203c by two different staining protocols, one protocol for
detection of surface expression of CD63 and CD203c (see above),
and one for detection of cytoplasmic (intracellular) CD63 and
CD203c. For detection of intracellular CD63 and CD203c, intact
cells were first incubated with unlabeled mAb against CD63 and
CD203c for 15 minutes at 4uC (to block surface antigens), washed,
and then permeabilized with methanol. Thereafter, cells were
stained with fluorochrome-conjugated antibodies against CD63
and CD203c (30 minutes at RT). Apoptosis was measured in
drug-exposed cells by combined AnnexinV/PI staining as reported
[36]. For cell cycle studies, drug-exposed cells were resuspended in
500 mL permeabilization buffer (0.1% Na-acetate and 0.1%
Triton X-100). Then 40 ml PI were added, and cell cycle
distribution analyzed on a FACSCalibur.
Western blot analysis
Prior to Western blotting, HMC-1 cells and KU812 cells (each
10
6 cells/ml) were incubated with control medium, NVP-BEZ235
(1 mM) or RAD001 (1 mM) at 37uC for 4 hours. Then, Western
blotting was performed as described [36] using a polyclonal
antibody against pAkt (S473) (Santa Cruz, Santa Cruz, CA), a
mAb against pAkt (193H12), a polyclonal antibody against Akt
(Cell Signaling, Danvers, MA), a mAb against pSTAT5 (clone 47),
a mAb against total STAT5 (clone 89), a mAb against pS6 (N7-
548) (all from Becton Dickinson Biosciences), and a polyclonal
rabbit antibody against b-Actin (Sigma-Aldrich, St. Louis, MO).
Additional Western Blot experiments were performed using
polyclonal antibodies against pERK (Thr202/Tyr204), total
ERK, p4EBP1 (Ser65) and pp70S6K (Thr389). All antibodies
were from Cell Signaling. Antibody reactivity was made visible by
sheep anti-mouse IgG or donkey anti-rabbit IgG and Lumingen
PS-3 detection reagent (GE Healthcare).
Evaluation of b-hexosaminidase release from cultured
MC
After incubation with NIP(5)-BSA-specific IgE (Jw8, 10 mg/ml)
and IL-4 (25 ng/ml) overnight, MC were incubated with NVP-
percent-inhibition of anti-IgE-induced upregulation of CD63 or CD203c on MC, and represent the mean6S.D. from three (cultured MC) or five (lung
MC) independent experiments. Asterisk (*): p,0.05. C: Ficoll-isolated BA (left panel) and lung MC (right panel) were preincubated in control medium
(Co) or with 10 mM NVP-BEZ235 at 37uC for 15 minutes. Then, cells were exposed to control medium or anti-IgE antibody E-124.2.8 (1 mg/ml) for
another 15 minutes (37uC). Thereafter, cells were stained with mAb directed against CD63 or CD203c and analyzed by flow cytometry using a
multicolor surface staining protocol and a cytoplasmic staining protocol. Results show SI values of surface CD63 (white bars), cytoplasmic CD63 (black
bars), surface CD203c (light grey bars) and cytoplasmic CD203c (dark grey bars) and represent the mean6S.D. from three independent experiments.
doi:10.1371/journal.pone.0029925.g009
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medium for 30 minutes (37uC). Then, cells were washed and
challenged with NIP(5)-BSA (100 ng/ml) for 90 minutes (37uC).
Thereafter, cell-free supernatants were collected and b-hexosa-
minidase release determined as reported [42].
Histamine release experiments
Before activated, MC were incubated with human IgE (Jw8,
10 mg/ml) and IL-4 (25 ng/ml) overnight (37uC) to induce IgE-
receptor expression [42]. Dextran-enriched blood BA (1610
6/ml)
and IgE-loaded MC (1610
5/ml) were incubated in control
medium, NVP-BEZ235 (0.001–10 mM), RAD001 (0.001–10 mM),
LY294002 (0.01–30 mM), or wortmannin (0.0001–1 mM), at 37uC
for 30 minutes. Thereafter, cells were exposed to anti-IgE antibody
E-124.2.8 (BA: 1 mg/ml; MC: 10 mg/ml) in HRB or control buffer
(HRB) at 37uC for 30 minutes. BA from allergic patients were
incubated with recombinant Bet v 1 (0.1 mg/ml) (Biomay Vienna,
Austria) [50] or control buffer (HRB) for 30 minutes. In select
experiments, BA were challenged with Ca-ionophore A23187
(0.001–10 mg/ml) or C5a (0.01–100 nM) as reported [51]. In
another set of experiments, BA or MC were incubated with control
medium or NVP-BEZ235 (10 mM) for 30 minutes, and then were
exposed to various concentrations of anti-IgE (0.001–10 mg/ml) for
30 minutes. After incubation, cells were centrifuged at 4uC. Cell-
freesupernatantsandsuspensions werethen recovered,andsamples
(supernatants and cell lysates) examined for histamine content by
RIA. Histamine release was calculated as percentage of released
histamine compared to total (cellular+extracellular) histamine. All
experiments were performed in triplicates.
Statistical analysis
To determine the level of significance in drug inhibition
experiments, standard statistical tests including the Student’s t
test, were applied. A p value of less than 0.05 was considered to
indicate statistical significance.
Supporting Information
Figure S1 Effects of LY294002 and wortmannin on
proliferation of HMC-1 cells and KU812 cells. HMC-1.1
cells (left panels), HMC-1.2 cells (middle panels), and KU812 cells
(right panels) were cultured incontrol medium (Co), control medium
with DMSO control (DMSO Co), or with increasing concentrations
of LY294002 (0.1 mM–20 mM) or wortmannin (0.001–1 mM) at
37uC for 48 hours. Thereafter,
3H-thymidine uptake was measured.
Results show the percentage of
3H-thymidine uptake compared to
control (Co) and represent the mean6S.D. of three independent
experiments in each cell line. Asterisk (*): p,0.05.
(TIF)
Figure S2 Effects of NVP-BEZ235, RAD001, LY294002
and wortmannin on cell cycle analysis of HMC-1 cells
and KU812 cells. Cell cycle distribution in HMC-1.1 cells
(upper panel), HMC-1.2 cells (middle panel) and KU812 cells
(lower panel) after exposure to control medium (Co) or various
concentrations of NVP-BEZ235 and RAD001 (left panels) as well
as LY294002 and wortmannin (right panels) as indicated, at 37uC
for 48 hours. Cell cycle distribution was analyzed by flow
cytometry as described in the text.
(TIF)
Figure S3 Effects of NVP-BEZ235 and RAD001 on
expression of pERK in HMC-1 cells and KU812 cell.
KU812 cells (left panel), HMC-1.2 cells (middle panel), and HMC-1.1
cells (right panel) were cultured in the absence or presence of NVP-
BEZ235 (1 mM) and RAD001 (1 mM) at 37uC for 4 hours.
Thereafter, cells were lysed and Western blotting was performed
using antibodies against pERK and total ERK as described in the text.
(TIF)
Figure S4 Effects of LY294002 and wortmannin on IgE-
mediated histamine release in human BA. BA obtained
from healthy donors (n=3) were preincubated with control
medium (Medium Co) or various concentrations of LY294002
(left panel) and wortmannin (right panel) as indicated at 37uC for
30 minutes. Afterwards, cells were exposed to anti-IgE (1 mg/ml)
at 37uC for 30 minutes. After centrifugation, histamine concen-
trations were determined in supernatants and cell-lysates by
radioimmunoassay. Histamine release is expressed as percentage
of total histamine. Results represent the mean6S.D. from three
donors. Asterisk (*) indicates p,0.05.
(TIF)
Figure S5 Effects of LY294002 and wortmannin on
expression of activation-linked cell surface antigens on
human BA and on expression of CD63 on KU812 cells.
(A): BA in whole blood samples were preincubated in control
medium (Medium Co) or in medium containing various
concentrations of LY294002 (0.01–30 mM; upper panels) or
wortmannin (0.0001–1 mM; lower panels) at 37uC for 15 minutes.
Then, cells were exposed to anti-IgE antibody E-124.2.8 (1 mg/ml)
for another 15 minutes (37uC). Thereafter, cells were stained with
monoclonal antibodies directed against CD63 (left panels) or
CD203c (right panels), and analyzed by multicolor flow cytometry
as described in the text. Basophils were defined as CD203c-
positive cells in all samples. Anti-IgE-induced upregulation of CD
antigens was calculated from mean fluorescence intensities (MFIs)
obtained with stimulated (MFIstim) and unstimulated (MFIcon-
trol) cells and was expressed as stimulation index (SI=MFIs-
tim:MFIcontrol). Results show SI values and represent the
mean6S.D. from three donors. Asterisk (*) indicates p,0.05
compared to Medium control. (B): KU812 cells were cultured in
control medium (Co), LY294002 (20 mM), wortmannin (1 mM), or
NVP-BEZ235 (0.001–10 mM) at 37uC for 24 hours (black bars) or
48 hours (open bars). After incubation, cells were stained with
anti-CD63 antibody and analyzed by flow cytometry. Results
show staining index (MFI corrected for the isotype control) and are
expressed as mean6S.D of three independent experiments.
Asterisk (*) indicates p,0.05.
(TIF)
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